LONDON, Dec 10 (Reuters) - GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research), Europe’s biggest drugmaker, continued its recent rapid pace of deal-making on Monday by signing two new early-stage biotech alliances in cancer and anti-infective medicine.
